tazarotene · Chartwell Rx · NDA 020600, 021184
Tazorac
Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 214560, Solaris Pharma Corp · 021184-001Approved 24 Nov 2025Detected 25 Oct 2026Historical import
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020600 · 001 · RLD | gel, topical | 0.05% | open |
| 020600 · 002 · RLD | gel, topical | 0.1% | open |
| 021184 · 001 · RLD | cream, topical | 0.05% | open |
| 021184 · 002 · RLD | cream, topical | 0.1% | open |